OBJECTIVES: To further investigate the role, if any, of acetylcholine and the parasympathetic nervous system in modulating b b-cell secretion in man. DESIGN: Oral glucose load (OGTT, 100 g p.o. at 0 min ) alone and preceded by pyridostigmine (PD, 120 mg p.o., 60 min before OGTT), a cholinesterase inhibitor, were administered on two different occasions, in random order, two or three days apart. SUBJECTS: Ten women with central obesity (OB, body mass index(BMI): 34.3 AE 2.1 kgam 2 , waist to hip ratio (WHR): 0.83 AE 0.01, aged 39.0 AE 5.3 y) and six normal women (NS, BMI: 22.7 AE 1.9 kgam 2 , WHR: 0.74 AE 0.01, aged 37.1 AE 4.8 y) were studied. MEASUREMENTS: Serum insulin, plasma glucose and plasma noradrenaline (NA) were measured at 760, 715 and 0 min, and then every 15 min up to 120 min. Insulin concentrations were measured in duplicate by immunoradiometric assay, glucose by glucose oxidase colorimetric method and NA was assayed after extraction with alumina using high performance liquid chromatography with electrochemical detection. Pulse rate (PR), systolic (SBP) and diastolic blood pressure (DBP) were also measured every 15 min during the tests by an automated cuff device. RESULTS: OGTT raised glucose concentrations in OB and NS (incremental area: 420 AE 44 vs 288 AE 70 mmolal. 2 h, respectively) without signi®cant differences between groups(F 0.6, P ns). On the other hand, OB showed an insulin response to OGTT higher than NS (10 120 AE 1074 vs 6692 AE 1962 m mU ml 7 1 2 h, respectively P`0.01). After OGTT alone NA concentrations increased to the same extent in NS (peak vs basal: 1.40 AE 0.16 vs 1.07 AE 0.10 nmolal, P`0.05) and in OB (peak vs basal: 1.50 AE 0.14 vs 1.04 AE 0.18 nmolal P`0.05). Both in NS and in OB, PD administration failed to modify basal glucose and insulin (P ns for both) as well as basal NA concentrations. In NS, the combined administration of PD and OGTT did not modify glucose and insulin responses compared to OGTT alone 335 AE 65.4 mmolal. 2 h and 6348 AE 1384 m mU ml 7 1 2 h, respectively) while in OB, PD signi®cantly increased the insulin response to OGTT (14640 AE 3030 mU ml 7 1 2 h, P`0.03), while the glucose response was not signi®cantly different from OGTT alone (478 AE 45 mmolal. 2 h). PD administration did not modify the NA response to OGTT, in NS or OB (P ns). In both groups, pyridostigmine administration did not affect systolic or diastolic blood pressures, but decreased pulse rate to the same extent in NS (74 AE 2 vs 66 AE 2 beatsamin, P`0.05) and in OB (72 AE 1 vs 67 AE 2 beatsamin, P`0.05). CONCLUSIONS: Our present data indicate that in man, as in animals, acetylcholine has a stimulatory in¯uence on insulin secretion.
Introduction
Several in vitro and in vivo studies in animals indicate that acetylcholine plays a stimulatory role on insulin secretion. 1±4 In fact, vagal stimulation enhances insulin release and its effect is antagonized by cholinergic antagonists in the rat. 1±4 Moreover, cholinergic agonists strikingly enhance both spontaneous and stimulated insulin secretion from rat b-cells in vitro. 3, 5 In fact, the parasympathetic nervous system has been hypothesized to be able to increase the preabsorptive insulin response to food ingestion 6 andaor to act via incretin release. 7 On the other hand, it has been hypothesized that a cholinergic alteration could play a role in causing insulin hypersecretion in obesity. 8À10 Data about the cholinergic control of insulin secretion in man are more contradictory. In fact, edrophonium, a cholinesterase inhibitor, and atropine have been found to be able to increase and reduce, respectively, basal insulin levels without affecting beta-cell responsiveness to the hyperglycaemic clamp. 11 Moreover, atropine and pirenzepine, muscarinic antagonists, were found unable to modify glucose-and mealstimulated insulin release by some but not by other authors.
12±16 Recently, at variance with some data, 11, 16, 17 we found that, in obesity, pirenzepine is unable to affect the exaggerated insulin responsiveness to intravenous glucose, as well as to an arginine load, while it signi®cantly decreases the early insulin response to an oral glucose load. 18 Based on the foregoing, in order to further clarify the role, if any, of acetylcholine in modulating insulin secretion in man, we studied the effect of pyridostigmine, a cholinesterase inhibitor, on the insulin and glucose responses to an oral glucose load both in normal subjects and in patients with abdominal obesity. Obese women were on a free diet and were free from diseases other than obesity. None was taking any medication.
Methods
The study protocol had been approved by the Ethical Committee of our Department and all subjects gave their informed consent to participate.
All subjects underwent an oral glucose load (OGTT, 100 g at 0 min) and OGTT plus pyridostigmine (PD, 120 mg p.o. at±60 min) tests in random order, two or three days apart. After an overnight fast, all tests were begun in the morning, starting at 08.00 and 08.30 h, 30 min after cannulation of a cubital vein kept patent by slow infusion of isotonic saline. Blood samples were taken at 760, 715 and 0 min, and then every 15 min up to 120 min for insulin, glucose and noradrenaline (NA) assay at each time point. Pulse rate (PR), systolic (SBP) and diastolic blood pressure (DBP) were also measured every 15 min during the tests by an automated cuff device (Lifestat 200-Physiocontrol, Redmond, WA, USA).
Serum insulin (mUaml) was measured in duplicate by immunoradiometric assays provided by Sorin Biomedica, Saluggia, Italy. The sensitivity of the insulin assay was 2.5 AE 0.3 mUaml. The inter-and intra-assay coef®cients of variation were 6.2±10.8% and 5.5± 10.6%, respectively.
Plasma glucose (mmolal) was measured by glucose oxidase colorimetric method (Gluco®x, by Menarini Diagnostics, Firenze, Italy).
Plasma NA concentrations (nmolal) were assayed after extraction with alumina using high performance liquid chromatography with electrochemical detection. The intra-and inter-assay coef®cients of variation for NA, assay were 3% and 7.0%, respectively.
Results are expressed as mean AE s.e.m. for all the variables examined. Incremental areas under the curves for glucose and insulin were calculated using trapezoidal integration. All data were evaluated by multivariate two-way ANOVA, paired or unpaired Student's t test where appropriate. Insulin data were also evaluated after log transformation.
Results
Basal glucose concentrations in OB and NS were not different, while basal insulin was higher in OB than in NS (P`0.05, Figure 1 and Figure 2 ). OGTT raised glucose concentrations both in OB and NS (incremental area: 7564 AE 790 vs 5184 AE 1260 mgadl 2 h, respectively) without signi®cant differences between groups (F 0.6) (Figure 1) .
On the other hand, the insulin response to OGTT in OB was higher than that in NS (10 120 AE 1074 vs 6692 AE 1962 mUaml 2 h, respectively, F 9.7, P`0.01; Figure 2 ). NA concentrations signi®cantly increased after OGTT, both in NS (peak vs basal: 1.40 AE 0.16 vs 1.07 AE 0.11 nmolal, P`0.05) and in OB (peak vs basal: 1.50 AE 0.14 vs 1.04 AE 0.18 nmolal, P`0.05). PD administration failed to modify basal glucose, insulin and NA concentrations both in NS and OB.
In NS, PD did not signi®cantly modify the glucose and insulin responses to OGTT (335 AE 65 vs 288 AE 70 nmolal 2 h and 6348 AE 1384 vs 6692 AE 1962 mUaml 2 h, respectively) while in OB, PD signi®cantly increased the insulin response to OGTT (14 640 AE 3030 vs 10 120 AE 1074 mUaml 2 h, P`0.03; Figure  2) ; the glucose response in OB was not signi®cantly different from OGTT alone (478 AE 45 vs 420 AE 44 mmolal. 2 h; Figure 1 ).
Both in NS and in OB, PD failed to modify the OGTT-induced increase in NA concentrations 
Side effects
Transient mild abdominal pain was observed in one normal subject after PD administration. No medical intervention was required.
Discussion
Our present data demonstrate that the cholinergic enhancement produced by pyridostigmine does not modify basal insulin and glucose concentrations, but it is able to potentiate the insulin response to OGTT in obese but not in normal subjects. Interestingly, the pyridostigmine-induced enhancement of the insulin response to OGTT takes place without any change in the glucose response. It is widely accepted that both basal and OGTTinduced insulin concentrations are exaggerated in obesity (References 19±21 and present data). In this condition the insulinaglucose ratio is also increased, in agreement with the existence of peripheral insulin resistance (References 19±21 and present data).
Among mechanisms involved in the pathogenesis of insulin hypersecretion in obesity, the existence of an altered neural control of beta-cell function has been hypothesized.
8±10
On the other hand, the role in man, if any, acetylcholine in the control of insulin secretion is still unclear either in physiological conditions or in obesity.
In the present study, we found that the insulin responsiveness to OGTT is increased by pyridostigmine in obese but not in normal subjects. This ®nding is unlikely to be due to glucose variations; in fact, the plasma glucose response to OGTT was unchanged after pyridostigmine pretreatment. Similarly, a catecholaminergic mechanism is unlikely to be involved in the pyridostigmine-induced enhancement of the insulin response to OGTT. In fact, in agreement with other data, 22 NA concentrations increased after OGTT alone and were not modi®ed by pyridostigmine pretreatment.
Two possible explanations could be given for the enhancing effect of pyridostigmine on the insulin response to OGTT in obese but not in normal subjects. In agreement with recent data on the rat, 23 this could be due to a direct sensitizing effect of acetylcholine to the effect of glucose on beta cells. Alternatively, based on evidence showing an important cholinergic in¯uence on incretin secretion, 7 as well on the well known in¯uence of incretins on insulin secretion, 24 an incretin-mediated mechanism could be hypothesized to explain the potentiating effect of pyridostigmine on the beta-cell response to OGTT in obesity. Actually, though it is well known that acetylcholine regulates gastrointestinal motility, 25 in the present study, stomach emptying rate was not evaluated. However, no alteration in the OGTT-induced glucose peak was found after PD pretreatment; this ®nding seems to be against the possibility that cholinergic enhancement modi®ed glucose absorption.
Our present data indicating that the enhancement of cholinergic activity by pyridostigmine, further increases the exaggerated OGTT-induced insulin secretion in obesity, but not in normal conditions, are against a major role of acetylcholine in the physiological control of insulin secretion.
14±16 On the other hand, it remains possible that a cholinergic alteration plays a role in the exaggerated insulin secretion which characterises obesity. 15±17 In fact, intravenous atropine administration was found to suppress basal insulin release more markedly in obese patients than in normal controls. 11 Moreover, cholinergic blockade with pirenzepine was reported to inhibit the insulin response to a mixed meal to a greater extent in obese non-insulin-dependent diabetics and in obese women with policistic ovarian syndrome than in normal subjects. 16, 17 Again, there is evidence in animals, showing a direct stimulatory effect of acetylcholine on beta-cell secretion. 23 Against this hypothesis, no effect of muscarinic blockade on insulin concentrations during intravenous glucose infusion both in normal and obese subjects, has been found. 12, 13 In a recent study in obese patients 18 , we showed that pirenzepine fails to modify the insulin hyperresponsiveness to intravenous glucose, as well as to arginine load, though it is able to reduce the early insulin response to an oral glucose load 18 . While the role of acetylcholine in the exaggerated insulin secretion in obesity is still unclear, our present ®ndings indicate that insulin hypersecretion is further enhanced by cholinergic activation. Thus, it could be speculated that acetylcholine plays a role in the control of insulin secretion in humans but, while it is of minor importance in physiological conditions, it becomes apparent only in insulin hypersecretory conditions such as in obesity.
In conclusion, our present data indicate that, like in the animal, also in man, acetylcholine plays some stimulatory in¯uence on insulin secretion.
